Memo Therapeutics Raises CHF 20M; Increases Series C to CHF 45M finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Memo Therapeutics increases Series C financing to CHF 45 million sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.
Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysisaXess is a restorative arteriovenous.
Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS).